UM: Targeting CARM1 Inhibits AML and Spares Normal Cells

UM: Targeting CARM1 Inhibits AML and Spares Normal Cells

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that inhibiting the enzyme CARM1 (also called PRMT4) dramatically slows acute myeloid leukemia (AML) progression but does not affect normal blood production.

Full Story

Related posts

UM Receives $1.7 Million NIH Grant to Study Relationship between Itch and Anxiety

Tasuku Akiyama, Ph.D., assistant professor in the Department of Dermatology and Cutaneous Surgery at the…

SBP: Cancer cells lure in nutrient-rich neighbors, then mug them

Despite living in a low-nutrient environment, cancer cells draw neighboring stroma cells—the glue-like cells holding…

UF: Using technology to stop deadly fake pills

Researchers with the University of Florida’s Herbert Wertheim College of Engineering have developed a way…